Public Companies
Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program
Christain Angermayer gave some clarification on PCN-101, atai’s ketamine program, hinting at new direction for the compound.
The post Christian Angermayer…
“atai’s management believes these data support the concept of at-home use of PCN-101 in future studies.” – Christian Angermayer
Yesterday we reported on results from atai’s new Phase 1 study of its PCN-101 ketamine compound. The drug had disappointing trial results back in January and the company has been researching where to go next with one of its (formerly?) most promising drugs.
atai announced results from Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 study looked at PCN-101 delivered subcutaneously compared to PCN-101 delivered intravenously (the previous trial with lackluster results was done intravenously).
Results were promising, showing that subcutaneous injection (directly into the body, like an injection into the arm) could have more efficient results than IV delivery.
But what do these early results mean for the PCN-101 program? This is what ATAI investors have been wondering since January.
atai founder Christain Angermayer gave some clarification on this, giving hope that PCN-101 could be revived as an at-home alternative to Spravato.
Will atai now invest in new trials? Go the partnership route?
See his full comments below.
After some setbacks for @atai_life's R-Ketamine (PCN-101) earlier this year, I am very happy to see good news today.
Some background: We know that Ketamine works for depression. The approval of J&J’s Spravato/S-Ketamine and a growing market for Ketamine clinics (using both…
— Christian Angermayer (@C_Angermayer) August 9, 2023
The post Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program appeared first on Microdose.
ketamine depression investors invest atai-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment